| Literature DB >> 16819252 |
Toshiki Sera1, Yoichi Hiasa, Kojiro Michitaka, Ichiro Konishi, Kana Matsuura, Yoshio Tokumoto, Bunzo Matsuura, Takeshi Kajiwara, Toshikazu Masumoto, Norio Horiike, Morikazu Onji.
Abstract
A 59-year-old man developed acute hepatitis with reactivated hepatitis B virus (HBV) following administration of rituximab (anti-CD20 monoclonal antibody). The patient was diagnosed with malignant lymphoma in 1998, and virus marker testing indicated HBV surface antigen (HBsAg)-negative and anti-HBs antibody (anti-HBs)-positive results when chemotherapy including rituximab was started. Levels of aminotransferases were elevated, and HBsAg results turned positive. Despite therapy for late-onset hepatic failure, the patient died. Rituximab appears likely to have induced HBV reactivation in this case. Anti-viral agents should be administered for both HBsAg-positive and anti-HBs-positive patients who are scheduled to receive rituximab.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16819252 DOI： 10.2169/internalmedicine.45.1590
Source DB: PubMed Journal: Intern Med ISSN： 0918-2918 Impact factor: 1.271